Spring Bank is devoted to pioneering its proprietary SMNH chemistry platform to discover and develop novel therapies to improve the lives of patients worldwide. We aim to achieve this by using our expertise and experience in the identification of proteins implicated in various disease states and the design and development of potent SMNH compounds to bind to these proteins. We design our SMNH compounds to bind specifically to their intended proteins, producing high therapeutic benefit over current therapies. We are committed to the highest standards of scientific excellence and integrity for the benefit of patients and the medical community.
Our primary objective is to maintain our leadership position in developing SMNH therapeutics for the treatment of viral infections. To achieve this goal, we are pursuing the following strategies:
Advance the clinical development of SB 9200 for chronic HBV.
We are conducting our Phase 2a ACHIEVE clinical trial of SB 9200 in non-cirrhotic patients infected with chronic HBV in which patients first receive SB 9200 as a monotherapy for 12 weeks, followed by Viread as a monotherapy for 12 weeks. We expect to report top-line results from the first SB 9200 monotherapy dosing cohort of the Phase 2a clinical trial in the first half of 2017, and to report top-line results for all patients treated with SB 9200 alone in the first half of 2018. Subject to the results of the Phase 2a clinical trial and obtaining additional funding, we expect to initiate a Phase 2b clinical trial in the second half of 2018 in patients infected with chronic HBV to explore the use of SB 9200 as a monotherapy and in combination with Viread. The Phase 2a clinical trial is being conducted under our clinical trial collaboration with Gilead and the Phase 2b clinical trial will be conducted under the same collaboration.
Develop SB 11285, our lead STING agonist compound, as a potential immunotherapeutic agent for selected cancers.
We are developing SB 11285, a novel proprietary STING agonist, as a potential immunotherapeutic agent for the treatment of selected cancers. We believe SB 11285 could be an important addition to the current standard of care in the treatment of various cancers. We are currently conducting preclinical studies of SB 11285 in selected cancer models and hope to achieve preclinical proof-of-principle in relevant oncology models in 2017. Also, we are developing back-up compounds from our SMNH platform targeting the STING pathway.
Seek to enter into preclinical and clinical collaborations with third parties that are developing compounds with different pharmacological mechanisms of action than SB 9200 for the treatment of chronic HBV.
We are seeking to enter into collaborations to explore the potential clinical benefits of administering SB 9200 in combination with investigational agents with different mechanisms of action for the treatment of patients infected with chronic HBV.
Develop fixed-dose combinations of SB 9200 with Baraclude and with Viread for the treatment of chronic HBV.
We are pursuing the development of the co-formulation of SB 9200 with Baraclude and with Viread as potential fixed-dose combination products for the treatment of patients with chronic HBV who may benefit from the combined use of SB 9200 as an immunomodulatory agent, and Baraclude or Viread, as the antiviral agent. We anticipate that the fixed-dose combination product could result in enhanced patient compliance and potentially allow for the delivery of lower doses of the individual compounds for equivalent efficacy and a more favorable safety profile.
Develop additional SMNH candidates from our proprietary platform as antiviral and anti-inflammatory therapies.
We are developing next-generation analogs of SB 9200, including SB 9400, SB 9941 and SB 9946. These compounds are in preclinical development as antiviral agents. We also have identified SMNH compounds that act as phosphodiesterase type 4, or PDE4, inhibitors, which are enzymes that act as potential anti-inflammatory agents. In preclinical studies, each of these compounds have demonstrated potential for anti-inflammatory activity.
Investigate the potential use of SB 9200 in other viral diseases.
Subject to obtaining additional financing, we may explore the development of SB 9200 for the treatment of HDV, HIV latency and/or RSV. We believe that therapies such as SB 9200, which may cause loss or clearance of HBsAg, may play an important role in the treatment of HDV co-infected HBV patients. In addition, we believe that compounds such as SB 9200 that activate and induce RIG-I may play a role in disrupting HIV latency or dormancy, allowing for the potential treatment and eradication of the disease with antiviral regimens. If we determine to proceed with the development of SB 9200 for HIV latency, we would likely seek to collaborate with major research centers and third parties with significant expertise in HIV to explore the potential use of SB 9200 in the eradication of HIV.